Plasminogen and cell migration in vivo

Fibrinolysis and Proteolysis

Volumn 13, Issue 2, 1999, Pages 49-53

  Plow, E F ^a   Ploplis, V A ^a   Carmeliet, P ^a   Collen, D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; ENZYME INACTIVATION; GENE INACTIVATION; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR MODEL; WOUND HEALING;

EID: 0032988602     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(99)90079-6     Document Type: Review

References (47)

1. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
2. 3 binding to vitronectin. Nature 1996; 383: 441-443.
3. Deng G, Curriden SA, Wang SJ, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol 1996; 134: 1563-1571.
4. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-945.
5. Liotta LA, Goldfarb RH, Brundage GP, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-4636.
6. Goldfarb RH and Liotta L. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 1986; 12: 294-307.
7. Lee E, Vaughan DE, Parikh SH et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 1996; 78: 44-49.
8. Carmeliet P, Moons L, Lijnen R et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genet 1997; 17: 439-444.
9. Matsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL-1) activity and release of biologically active IL-1 from monocytes by trypsin and plasmin. J Immunol 1986; 136: 2883-2891.
10. 1 by plasmin. J Cell Biol 1990; 110: 1361-1367.
11. Syrovets T, Tippler B, Rieks M, Simmet T. Plasmin is a potent and specific chemoattractant for human peripheral monocytes acting via a cyclic guanosine monophosphate-dependent pathway. Blood 1997; 89: 4574-4583.
12. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807
13. Ploplis VA, Carmeliet P, Vazirzadeh S et al. Effects of disruption of the plasminogen gene in mice on thrombosis, growth and health. Circulation 1995; 92: 2585-2593.
14. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 1998; 91: 20005-2009.
15. Gyetko MR, Chen GH, McDonald RA et al. Urokinase is required for the pulmonary inflammatory response to crytococcus neoformans. J Clin Invest 1996; 97: 1818-1826.
16. Romer J, Bugge TH, Pyke C et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med 1996; 2: 287-292.
17. Romer J, Bugge TH, Pyke C et al. Plasminogen and wound healing. Nature Med 1996; 2: 725-727.
18. Watt FM Jones PH. Expression and function of the keratinocyte integrins. Dev Suppl 1993; 185-192.
19. 1 on endothelial cells. J Biol Chem 1997; 272: 5360-5366.
20. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJS, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996; 87: 709-719.
21. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-208.
22. Carmeliet P, Moons L, Dewerchin M et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor and the plasminogen system. Ann N Y Acad Sci 1997; 811: 191-206.
23. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
24. Okada SS, Tomaszewski JE, Barnathan ES. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp Cell Res 1995; 217: 180-187
25. Schneiderman J, Sawdey MS, Keeton MR et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
26. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar W, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
27. Schneiderman J, Bordin GM, Engelberg I et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm with a possible mechanism for aneurysm expansion. J Clin Invest 1995; 96: 639-645.
28. Shak PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 1997; 96: 2115-2117.
29. Xiao Q, Danton MJS, Witte DP et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 10335-10340.
30. Xiao Q, Danton MJS, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998; 101: 1184-1194.
31. Shi C, Russell ME, Bianchi C, Newell JB, Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res 1994; 75: 199-207.
32. Moons L, Shi C, Ploplis V et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest 1998; 102: 1788-1797
33. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992; 11: 291-311.
34. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-619.
35. Yu H and Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990; 50: 7623-7633.
36. Kobayashi H, Shinohara H, Takeuchi K et al. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res 1994; 54: 844-849.
37. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270-1278.
38. Hollas W, Hoosein N, Chung LWK et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 1992; 68: 662-666.
39. Min HY, Doyle LV, Vitt CR et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.
40. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
41. Rabbani SA, Harakidas P, Davidson D, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995; 63: 840-845.
42. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma. Cell 1994; 79: 315-328.
43. Bugge TH, Kombrinck KW, Xiao Q et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997; 90: 4522-4531.
44. Poggi A, Bellelli E, Salvatore L et al. Reduced pulmonary metastases of Lewis Lung carcinoma in hPAI-1 transgenic mice. Fibrinolysis 1994; 8 (suppl 1): #283 (Abstract).
45. Montgomery AMP, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993; 53: 693-700.
46. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997; 71: 116-122.
47. Bugge TH, Lund LR, Kombrinck KK et al. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16: 3097-3104.